VMTHF (Venus Medtech (Hangzhou)) ROCE %: -20.69% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VMTHF Venus Medtech (Hangzhou) Inc VMTHF
52 GF Score
Price $0.42
GF Value $1.27
! 4 Warning Signs
View Full Analysis

What is Venus Medtech (Hangzhou) ROCE %?

Venus Medtech (Hangzhou) VMTHF 52 ROCE % is -20.69% as of Dec. 2025. GuruFocus rates VMTHF with a GF Score™ of 52/100 and a GF Value™ of $1.27. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Venus Medtech (Hangzhou)'s annualized ROCE % for the quarter that ended in Dec. 2025 was -20.69%.

Venus Medtech (Hangzhou)  (OTCPK:VMTHF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Venus Medtech (Hangzhou) ROCE % Related Terms

Venus Medtech (Hangzhou) ROCE % Historical Data

* Premium members only.

The historical data trend for Venus Medtech (Hangzhou)'s ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Venus Medtech (Hangzhou) ROCE % Chart

Venus Medtech (Hangzhou) Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only -8.62 -21.89 -15.80 -22.05 -15.26

Venus Medtech (Hangzhou) Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.75 -11.53 -33.02 -9.44 -20.69
VMTHF
52GF Score
Venus Medtech (Hangzhou) Inc VMTHF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Venus Medtech (Hangzhou) ROCE % Calculation

Venus Medtech (Hangzhou)'s annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-54.957/( ( (446.354 - 49.686) + (357.72 - 34.161) )/ 2 )
=-54.957/( (396.668+323.559)/ 2 )
=-54.957/360.1135
=-15.26 %

Venus Medtech (Hangzhou)'s ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-72.604/( ( (434.518 - 56.17) + (357.72 - 34.161) )/ 2 )
=-72.604/( ( 378.348 + 323.559 )/ 2 )
=-72.604/350.9535
=-20.69 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -20.69% mean?
Venus Medtech (Hangzhou) (VMTHF) has a ROCE % of -20.69% as of Dec. 2025.
Is Venus Medtech (Hangzhou)'s ROCE % too high?
Venus Medtech (Hangzhou)'s current ROCE % is -20.69%. Overall, Venus Medtech (Hangzhou) has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Venus Medtech (Hangzhou)'s ROCE % compare to ABT and SYK?
Venus Medtech (Hangzhou)'s ROCE % of -20.69% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.18. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.18, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venus Medtech (Hangzhou)'s current ROCE % is -20.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Medtech (Hangzhou) stock overvalued right now?
Venus Medtech (Hangzhou) (VMTHF) has a current ROCE % of -20.69%. The stock's GF Value™ is $1.27, compared to a current price of $0.42 — trading 66.8% below its estimated fair value. The current ROCE % is -20.69%. Venus Medtech (Hangzhou)'s overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Venus Medtech (Hangzhou) (VMTHF), the current ROCE % is -20.69% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Venus Medtech (Hangzhou) (VMTHF) Overvalued in 2026?

Based on GuruFocus' analysis, Venus Medtech (Hangzhou) stock appears to be undervalued. The current stock price of $0.42 is trading 66.8% below its estimated GF Value™ of $1.27.

Key valuation signals for VMTHF:

  • ROCE %: -20.69%
  • GF Value™: $1.27 vs. price of $0.42 (66.8% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the VMTHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Venus Medtech (Hangzhou) Business Description

Other Exchanges 02500:Hong Kong
Address No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051
Venus Medtech (Hangzhou) Inc is engaged in the medical devices that integrate R&D, clinical development, manufacturing, and commercialization. The company has developed a product portfolio covering the interventional devices for valvular heart diseases, including transcatheter aortic valve replacement (TAVR), transcatheter pulmonary valve replacement (TPVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), and other procedural accessories, allowing it to provide overall solutions for physicians and patients. Geographically, the company operates in mainland China, Israel, Hong Kong, the USA, and the Netherlands. The majority of the revenue is derived from Mainland China.
52GF Score

Get the complete analysis for VMTHF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price
$1.27
GF Value